ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical

Myostatin Propeptide

Myostatin Propeptide

Also known as: GDF-8 Propeptide, MSTN Propeptide, Myostatin Inhibitor Propeptide

Overview

Key Facts

Primary Goal: Research and therapeutic applications of Myostatin Propeptide

Binds directly to the mature myostatin dimer, forming an inactive latent complex. Prevents myostatin from engaging ActRIIB receptors on muscle fibers.

Dosing Information

Half-Life

Estimated 2-4 hours (short, no Fc fusion)

Typical Dose

50–200 mcg

Frequency

Once daily (research dosing, not clinically established)

Cycle Length

4-8 weeks (research protocols only)

Administration Routes:
subcutaneousintramuscular

Benefits

  • Highly specific myostatin inhibition without broad TGF-beta pathway disruption
  • Reduced off-target side effect profile compared to ActRIIB decoys
  • Potential for muscle wasting therapy with fewer vascular complications
  • Preserves activin and BMP signaling pathways
  • May enhance muscle regeneration post-injury

Side Effects

Limited human safety data availablemild
Injection site reactionsmild
Possible mild immune response to exogenous proteinmild
Theoretical concern of incomplete myostatin neutralization at lower dosesmild

Mechanism of Action

1

Binds directly to the mature myostatin dimer, forming an inactive latent complex

2

Prevents myostatin from engaging ActRIIB receptors on muscle fibres

3

Highly specific — does not significantly inhibit activin, GDF-11, or BMPs

4

Relieves Smad2/3-mediated transcriptional repression of muscle-specific genes

Contraindications

Do not use this peptide if any of the following apply:

  • Active malignancy
  • Pregnancy or breastfeeding
  • Known hypersensitivity to recombinant proteins

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Preclinical

The myostatin propeptide has been extensively studied in animal models. Transgenic mice overexpressing the propeptide exhibit 20-40% increases in muscle mass. Engineered variants with enhanced affinity (e.g., D76A mutant) show even greater efficacy. While no direct clinical trials of the injectable peptide exist, gene therapy approaches delivering the propeptide are in preclinical development for muscular dystrophies.

Frequently Asked Questions

Common questions about Myostatin Propeptide

UK-Specific Information

Exclusive data points and guidance for UK residents using Myostatin Propeptide

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok